Medical devices employing novel polymers

• US 7,985,415 B2
• Filed: 11/18/2003
• Issued: 07/26/2011
• Est. Priority Date: 09/10/1997
• Status: Expired due to Fees

• Current Assignee: Rutgers University
• Original Assignee: Rutgers University
• Inventors: Giroux, Karen J.
• Primary Examiner(s): Fubara; Blessing M
• Application Number:
  US10/716,577
• Publication Number:
  US 20060188546A1
• Time in Patent Office: 2,807 Days
• Field of Search: 424/426
• US Class Current: 424/426
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 2300/604 Biodegradation
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

Medical devices with at least one surface comprising a polymer or polymers on the surface are provided. The polymer or polymers are capable of breaking down (e.g., including, but not limited to, hydrolyzing) in the physiologic milieu to form an active agent or agents under physiologic conditions, and can contain other active agents dispersed within or appended to the polymer matrix. Methods of delivering an active agent to an interior surface of a vein or artery are also provided.

Claims

1. A medical device having at least one surface, comprising:

1) a polymer comprising salicylic acid incorporated into the polymer backbone on all or a portion of the surface, wherein the salicylic acid is disassociated from the polymer upon hydrolysis; and

     2) a second active agent selected from paclitaxel and rapamycin that is dispersed within the polymer matrix of the polymer such that the second active agent is released upon degradation of the polymer.

2. The medical device of claim 1, wherein the medical device is a stent.

3. A stent of claim 2, comprising at least two or more surfaces.

4. A stent of claim 3, wherein all or a portion of the two or more surfaces are covered with the polymer.

5. A stent of claim 4, wherein the polymer covers all or a portion of the surface in a thickness of about 100 nm to 1 cm.

6. A stent of claim 4, wherein the polymer covers all or a portion of the surface in a thickness of about 0.5 μ

m to about 2.0 mm.

7. A stent of claim 4, wherein the active agent is disassociated from the polymer over a period of about 2 days to about 2 years.

8. The medical device of claim 1, wherein the polymer covers all or a portion of the surface in a thickness of about 100 nm to 1 cm.

9. The medical device of claim 1, wherein the polymer covers all or a portion of the surface in a thickness of about 0.5 μ

m to about 2.0 mm.

10. The medical device of claim 1, wherein the salicylic acid is disassociated from the polymer over a period of about 2 days to about 2 years.

11. A medical device of claim 1, wherein a third active agent is dispersed within the polymer matrix of the polymer such that the third active agent is released upon degradation of the polymer.

12. A medical device of claim 1, wherein a third active agent is appended to the polymer such that the third active agent is released under physiological conditions.

13. The device of claim 1 wherein the second agent is paclitaxel.

14. The device of claim 1 wherein the second agent is rapamycin.